December 2nd 2024
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Progress continues in treating pediatric skin ailments
April 1st 2006National report ? While topical calcineurin inhibitors for treating atopic dermatitis (AD) continue to grab headlines, sources tell Dermatology Times that research into additional treatments for pediatric skin problems is progressing.
Ethnic pediatric patients benefit from tailored treatment plan
March 1st 2006Dermatologists will inevitably increase compliance among ethnic patients when treating scalp conditions such as seborrheic dermatitis or atopic dermatitis if they inquire about the types of hair products the patient normally uses.
TCIs' 'black box' signals caution
March 1st 2006National report -- Dermatologists likely will exercise more caution in prescribing the topical calcineurin inhibitors (TCIs) Elidel cream (pimecrolimus, Novartis) and Protopic ointment (tacrolimus, Astellas Pharma) in response to the Food and Drug Administration's decision to add "black box" warnings to these drugs' labels, an expert tells Dermatology Times.
Cosmetic trend here to stay, but at what cost?
March 1st 2006National report -- Economic realities will continue driving dermatologists to add cosmetic services and products to their practices, experts tell Dermatology Times. However, sources say this trend is creating concerns about the specialty's ethics, image and accessibility.
Hello, Perlane; goodbye, bruising
March 1st 2006It is a higher-viscosity hyaluronic acid manufactured by Q-Med, the same company that manufacturers Restylane for Medicis. Medicis purchased the marketing rights for Restylane in the United States and invested the time and money to get the filler approved. At some point, Medicis undoubtedly will obtain approval for Perlane and add this to its offerings.
Creative combinations, techniques expand filler possibilities
March 1st 2006New products in the pipeline will add more versatility to fillers, but until they arrive, Dr. Cohen suggests alternatives such as using a 32-gauge needle to fill in etched-in lines in the nasolabial folds and vertical lip lines.
'Tried-and-true' lasers still preferred for treating kids
March 1st 2006Harrison Hot Springs, British Columbia ? There have been many advances in laser technology for medical applications, but for the treatment of pediatric skin diseases, dermatologists are still turning to the "tried-and-true" pulsed dye, Q-switched pigment and CO2 lasers.
Ethnic pediatric patients benefit from tailored treatment plan
March 1st 2006Dermatologists will inevitably increase compliance among ethnic patients when treating scalp conditions such as seborrheic dermatitis or atopic dermatitis if they inquire about the types of hair products the patient normally uses.
Atopic dermatitis: Breaking it down
March 1st 2006National report ? More basic research into atopic dermatitis (AD) needs to be conducted to understand the subsets of the condition and to generate new therapies to expand the therapeutic choices for the patient, according to Lawrence Chan, M.D., professor and head of the department of dermatology at the University of Illinois. Specifically, differentiating between "intrinsic" and "extrinsic" AD is critical.
Understanding geriatric dermatology
March 1st 2006San Francisco ? Treating the 65 and older patient is becoming a growing issue in dermatology. While some 35 million Americans ? about one in every eight people ? are elderly today, the senior population is expected to increase to one in five people, or an estimated 70 million, by 2030, according to Wendy E. Roberts, M.D., a dermatologist in Rancho Mirage and assistant clinical professor of medicine at Loma Linda University Medical School, Loma Linda, Calif.
AAD, NJMRC protest FDA's 'black box' warning on eczema drugs
February 7th 2006Washington -- The American Academy of Dermatology and the National Jewish Medical and Research Center have issued statements protesting new "black box" cancer warnings the Food and Drug Administration (FDA) has ordered on two drugs used to treat eczema: Elidel Cream (Novartis ) and Protopic ointment (Astellas Pharma).
Dermatologist says topical therapies safe for atopic dermatitis tx
February 1st 2006Portland, Ore. - Recently concerns have arisen regarding chronic use of the calcineurin inhibitors, Elidel cream (Novartis) and Protopic ointment (Astellas), in treating atopic dermatitis because of their potential association with infection and malignancy.